{"page_content": "71\nSASB TOPIC REPORTINGUNIT OF \nMEASURECODE\nNumber of recalls issued, total \nunits recalledAmgen discloses material, legal, and regulatory \nissues in its annual 10-K and quarterly 10-Qs\nPertinent reporting can be found in the \nCounterfeit Drug Statement on our websiteNumber\nn/aHC-BP-250a.3\nHC-BP-260a.1Total amount of product accepted for \ntake-back, reuse, or disposal\nDiscussion of process for alerting \ncustomers and business partners of \npotential or known risks associated \nwith counterfeit productsData on product accepted through take-back \ncan be found in the Product Sustainability \nsection of our website (see the Product \nPackaging and Life Cycle section); in addition \nwe provide information about the California Safe \nNeedle Collection and Disposal Plan\nPertinent reporting can be found in the \nCounterfeit Drug Statement on our websiteMetric tons \n(t)\nn/aHC-BP-250a.4\nHC-BP-260a.2Number of FDA enforcement actions \ntaken in response to violations \nof current Good Manufacturing \nPractices (cGMP), by type\nNumber of actions that led to \nraids, seizure, arrests, and/or filing \nof criminal charges related to \ncounterfeit productsAmgen discloses material, legal, and regulatory \nissues in its annual 10-K and quarterly 10-Qs\nAmgen discloses material, legal, and regulatory \nissues in its annual 10-K and quarterly 10-QsNumber\nNumberHC-BP-250a.5\nHC-BP-260a.3\nDrug Safety\nCounterfeit \nDrugsDescription of methods and \ntechnologies used to maintain \ntraceability of products throughout \nthe supply chain and prevent \ncounterfeitingAPPENDIX INTRODUCTION GOVERNANCECOVID- 19 \nRESPONSEBUSINESS \nETHICSETHICAL \nRESEARCHACCESS TO \nMEDICINEDIVERSITY, INCLUSION, \nAND BELONGINGENVIRONMENTAL\nSUSTAINABILITYRESPONSIBLE \nSOURCINGCOMMUNITY \nINVESTMENT\nACCOUNTING METRIC", "metadata": {"source": "NASDAQ_AMGN_2020.pdf", "page": 70, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}